Table 11.
Association between sponsor and clinical outcomes: Necrotizing enterocolitis, sepsis and antibiotic use
| Source of funding |
Positive* |
Neutral* |
Chi-square p value | Fisher’s exact p value | |
|---|---|---|---|---|---|
| n (%) $$ | n (%) $$ | ||||
| Necrotising enterocolitis N = 11 |
Industry |
|
4 (36.4) |
0.118 |
0.273 |
| |
None/Not clear |
|
3 (27.3) |
|
|
| |
Non industry |
2 (18.2) |
2 (18.2) |
|
|
| Sepsis N = 10 |
Industry |
|
2 (20) |
Not Valid |
|
| |
None/Not clear |
|
3 (30) |
|
|
| |
Non industry |
|
5 (50) |
|
|
| Antibiotic use N = 19 |
Industry |
4 (21.1) |
4 (21.1) |
0.031# |
0.039# |
| |
None/Not clear |
|
5 (26.3) |
|
|
| Non industry | 6 (31.6) |
$$ Overall percentage.
*Positive: synbiotic, probiotic or prebiotic supplementation had a statistically significant effect, p < 0.05. There were significant differences between study groups (in favour of experimental group).
*Neutral: synbiotic, probiotic or prebiotic supplementation did not have a statistically significant effect, p > 0.05, No significant differences between study groups.
# Significant p < 0.05.